|
|
Article: UK pharma major GlaxoSmithKline and US microRNA specialist Regulus Therapeutics have signed a worldwide alliance to develop and market microRNA therapeutics to treat inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel syndrome.
- Article from:
- Chemistry and Industry
- Article date:
- June 23, 2008
CopyrightCOPYRIGHT 2008 Society of Chemical Industry. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
UK pharma major GlaxoSmithKline and US microRNA specialist Regulus Therapeutics have signed a worldwide alliance to develop and market microRNA therapeutics to treat inflammatory diseases, such ...
Related newspaper, magazine, and journal articles:
|
|
Article: Regulus Therapeutics Achieves Initial Milestone in ...
Business Wire;
May 14, 2009 ;
700+ words
... ... immune cells CARLSBAD, Calif. -- Regulus Therapeutics Inc. today announced that it achieved ... number of serious human diseases. About Regulus Therapeutics Inc. Regulus Therapeutics Inc. is a biopharmaceutical company ...
|
|